Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Hospitalization Clear all
Completed Not applicable Interventional

Care Anywhere With Community Paramedics Program to Reduce Hospitalization

NCT05232799
View directory record Official record
Conditions
Acute Illness
Interventions
Care Anywhere with Community Paramedics program
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Barron, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 16, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents

NCT04592809
View directory record Official record
Conditions
Suicide, Attempted, Suicide and Depression, Suicide Threat
Interventions
Ketamine Hydrochloride, Midazolam Hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 16, 2026, 9:03 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

KIDney Injury in Times of COVID-19 (KIDCOV)

NCT04705766
View directory record Official record
Conditions
SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury
Interventions
Urine Collection
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 16, 2026, 9:03 PM EDT
Completed No phase listed Observational

Cardiac Function as Measured by Non-invasive Electrical Velocimetry Cardiac Monitor in Hospitalized Children

NCT01030445
View directory record Official record
Conditions
Cardiac Output, Blood Pressure
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Sep 16, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Results available

Budesonide Inhalation Suspension for Acute Asthma in Children

NCT00393367
View directory record Official record
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 16, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

NCT03345979
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil, Paliperidone Palmitate
Combination Product · Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 16, 2026, 9:03 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

NCT04948203
View directory record Official record
Conditions
Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
Interventions
Sirolimus
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 16, 2026, 9:03 PM EDT
Terminated Not applicable Interventional

Optimal Management of Pain in Hospitalized Patients - Opioid Tolerant Populations.

NCT02470728
View directory record Official record
Conditions
Pain, Acute Pain, Postoperative Pain
Interventions
New Clinical Pathway
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Orange, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 16, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 16, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

NCT02554890
View directory record Official record
Conditions
Acute Heart Failure
Interventions
sacubitril/valsartan (LCZ696), Enalapril, sacubitril/valsartan (LCZ696) matching placebo, enalapril matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
887 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
123
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 105 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 16, 2026, 9:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stroke and Cerebrovascular Diseases Registry

NCT03281590
View directory record Official record
Conditions
Stroke, Acute Stroke, Acute Brain Injury, Ischemic Stroke, Hemorrhagic Stroke, Transient Ischemic Attack, Subarachnoid Hemorrhage, Cerebral Ischemia, Cerebral Infarction, Cerebral Stroke, Venous Sinus Thrombosis, Cranial
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
1 Year and older
Enrollment
4,594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 16, 2026, 9:03 PM EDT
Enrolling by invitation Phase 1 Interventional

Nitrous Oxide- Suicidal Ideation

NCT03736538
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Mood Disorders, Suicidal Ideation
Interventions
Nitrous Oxide, Placebo gas
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 16, 2026, 9:03 PM EDT
Recruiting Phase 2 Interventional

Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension

NCT07511361
View directory record Official record
Conditions
Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Interventions
Tonlamarsen, Placebo
Drug
Lead sponsor
Kardigan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Arvada, Colorado • Homestead, Florida • Port Orange, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 16, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
87
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 16, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

A Study Of Acute Decompensated Heart Failure

NCT07572955
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Lung Ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 16, 2026, 9:03 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

NCT07161843
View directory record Official record
Conditions
Acute Renal Failure (ARF), Acute Tubular Necrosis
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
10 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rosharon, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 16, 2026, 9:03 PM EDT
Recruiting No phase listed Observational

COPD Exacerbation Follow Up

NCT07118306
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Not listed
Lead sponsor
Viz.ai, Inc.
Industry
Eligibility
40 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Park Ridge, Illinois • Cherry Hill, New Jersey • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 16, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

DRAIN: DRainage in Acute Decompensated Heart faIlure With Pleural effusioNs

NCT07419360
View directory record Official record
Conditions
Congestive Heart Failure(CHF), Pleural Effusion Due to Congestive Heart Failure
Interventions
Thoracentesis
Procedure
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 16, 2026, 9:03 PM EDT
Withdrawn Not applicable Interventional

Using Continuous Positive Airway Pressure to Reduce the Incidence of Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease

NCT01859260
View directory record Official record
Conditions
Chronic Kidney Disease, Obstructive Sleep Apnea
Interventions
CPAP/autopap
Device
Lead sponsor
University of South Florida
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2019 · Synced Sep 16, 2026, 9:03 PM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 16, 2026, 9:03 PM EDT
Completed Not applicable Interventional Results available

Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients

NCT01822197
View directory record Official record
Conditions
Depression, Cystic Fibrosis
Interventions
Phototherapy
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Sep 16, 2026, 9:03 PM EDT
Terminated Not applicable Interventional

Yoga Fatigue Study

NCT02134782
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse, Burkitt's Lymphoma Stage III, Burkitt's Lymphoma Stage IV, Type 3 Diffuse Large B-Cell Lymphoma
Interventions
Individualized Yoga Intervention Group, iPad Activity Control Group
Behavioral · Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
8 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 16, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729593
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 16, 2026, 9:03 PM EDT
Recruiting Not applicable Interventional

Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

NCT03836482
View directory record Official record
Conditions
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 16, 2026, 9:03 PM EDT